BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the…
Industry Peers
Drug Manufacturers - Specialty & Generic| Headline | Source | Time |
|---|---|---|
Older | ||
 BioSyent (CVE:RX) Has Announced That It Will Be Increasing Its Dividend To CA$0.055 BioSyent Inc. ( CVE:RX ) has announced that it will be increasing its dividend from last year's comparable payment on... | ||
Individual investors account for 57% of BioSyent Inc.'s (CVE:RX) ownership, while institutions account for 19% Key Insights The considerable ownership by individual investors in BioSyent indicates that they collectively have a... | ||
Investors in BioSyent (CVE:RX) have seen notable returns of 83% over the past three years One simple way to benefit from the stock market is to buy an index fund. But many of us dare to dream of bigger... | ||
Here's Why We Think BioSyent (CVE:RX) Might Deserve Your Attention Today Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks... | ||
Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)? BioSyent (CVE:RX) has had a rough month with its share price down 2.5%. However, a closer look at its sound financials... | ||
 BioSyent Second Quarter 2025 Earnings: EPS: CA$0.18 (vs CA$0.14 in 2Q 2024) BioSyent ( CVE:RX ) Second Quarter 2025 Results Key Financial Results Revenue: CA$10.2m (up 14% from 2Q 2024). Net... | ||